New drug combo for previously treated colorectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of a GSL synthesis inhibitor, an immunotherapy drug, and/or regorafenib in people with a specific type of colorectal cancer (pMMR/MSS) that has not responded to at least two prior treatments. The goal is to see if this new approach can help shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- Your colorectal cancer has spread or come back and has not responded to at least two prior treatments.
- Your tumor type is called pMMR or MSS (your doctor can check this).
- You have a certain liver enzyme type (CYP2D6) that is not ultra-rapid (your doctor can test this).
- You are willing to have a new tumor biopsy or provide a recent stored sample.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, KN 046 and regorafenib, in people with a type of advanced colorectal cancer that has not responded to previous treatments. The goal is to see if this combination can help shrink or control the tumor.
This trial tests a combination of two drugs, regorafenib and lorigerlimab, for people with colorectal cancer that has a positive blood test for cancer DNA after they have finished standard treatments. The goal is to see if this treatment can delay or prevent the cancer from coming back.
This trial tests a new combination of three drugs for people with advanced colorectal cancer that has not responded to previous treatments. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial tests a combination of a targeted therapy pill (TKI) and an immunotherapy (PD-1 inhibitor) for people with advanced colorectal cancer that has stopped responding to standard treatments. It uses a blood test to tailor the treatment, aiming to be more effective with fewer side effects.
This study tests a combination of two drugs (regorafenib and envafolimab) for gastrointestinal stromal tumors (a type of stomach/bowel cancer) that have stopped responding to standard treatments. The trial compares this combination to other doctor-selected treatments to see if it slows tumor growth.
This trial tests a combination of three drugs plus thymalfasin, an immune-boosting medicine, for people whose advanced colorectal cancer has not responded to at least two prior treatments. It's designed specifically for the common type of colorectal cancer (pMMR/MSS) to see if adding this immune therapy can help.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.